Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Dewar

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|April 17, 1999
In pursuit of excellence for patients with cancer: the Scottish Cancer Therapy Network modelP L Stroner, D H Brewster, J A Dewar, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 1987
Management of the axilla in conservatively treated breast cancer: 592 patients treated at Institut Gustave-RoussyJ A Dewar, D Sarrazin, E Benhamou, et al.
The British Journal of Surgery|August 1, 1986
Conservative management of breast cancerD Sarrazin, J A Dewar, R Arriagada, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1993
Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assayE M Hunter, L A Sutherland, I A Cree, et al.
British Journal of Cancer|July 1, 1996
Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast GroupH J Stewart, A P Forrest, D Everington, et al.
British Journal of Cancer|July 29, 2010
Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based studyC A Purdie, L Baker, A Ashfield, et al.
Cancer|December 1, 1995
Local relapse and contralateral tumor rates in patients with breast cancer treated with conservative surgery and radiotherapy (Institut Gustave Roussy 1970-1982). IGR Breast Cancer GroupJ A Dewar, R Arriagada, S Benhamou, et al.
Calcified Tissue International|September 18, 2007
The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone diseaseJ E Brown, E V McCloskey, J A Dewar, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapyA Fong, J Shafiq, C Saunders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa studyM Martin, P Fumoleau, J A Dewar, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|April 17, 1999
In pursuit of excellence for patients with cancer: the Scottish Cancer Therapy Network modelP L Stroner, D H Brewster, J A Dewar, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 1987
Management of the axilla in conservatively treated breast cancer: 592 patients treated at Institut Gustave-RoussyJ A Dewar, D Sarrazin, E Benhamou, et al.
The British Journal of Surgery|August 1, 1986
Conservative management of breast cancerD Sarrazin, J A Dewar, R Arriagada, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1993
Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assayE M Hunter, L A Sutherland, I A Cree, et al.
British Journal of Cancer|July 1, 1996
Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast GroupH J Stewart, A P Forrest, D Everington, et al.
British Journal of Cancer|July 29, 2010
Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based studyC A Purdie, L Baker, A Ashfield, et al.
Cancer|December 1, 1995
Local relapse and contralateral tumor rates in patients with breast cancer treated with conservative surgery and radiotherapy (Institut Gustave Roussy 1970-1982). IGR Breast Cancer GroupJ A Dewar, R Arriagada, S Benhamou, et al.
Calcified Tissue International|September 18, 2007
The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone diseaseJ E Brown, E V McCloskey, J A Dewar, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapyA Fong, J Shafiq, C Saunders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa studyM Martin, P Fumoleau, J A Dewar, et al.
Pageof 5